Literature DB >> 21257738

Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C.

Jacob Nattermann1, Martin Vogel, Hans Dieter Nischalke, Mark Danta, Stefan Mauss, Hans-Jörg Stellbrink, Axel Baumgarten, Christoph Mayr, Raffaele Bruno, Cristina Tural, Gerd Klausen, Bonaventura Clotet, Uwe Naumann, Thomas Lutz, Michael Rausch, Knud Schewe, Bernhard Bienek, Georg Haerter, Tilman Sauerbruch, Juergen K Rockstroh, Ulrich Spengler.   

Abstract

Recently, a IL28B (rs 12979860) gene polymorphism was identified as a predictor for response to hepatitis C virus-specific treatment in human immunodeficiency virus (HIV)-uninfected and -infected patients with chronic hepatitis C. In an analysis of HIV-infected patients with acute hepatitis C, we found that the IL28B genotype was associated with serum levels of hepatitis C virus RNA, g-GT, and CD4 cell count. In contrast to HIV-infected patients with chronic hepatitis C, the IL28B genotype was not significantly associated with treatment response rates in patients with acute hepatitis C. Thus, effects of the IL28B single-nucleotide polymorphism may differ in HIV-infected patients with chronic and acute hepatitis C.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21257738      PMCID： PMC3072731          DOI： 10.1093/infdis/jiq098

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  15 in total

1.  IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.

Authors:  Sergei V Kotenko; Grant Gallagher; Vitaliy V Baurin; Anita Lewis-Antes; Meiling Shen; Nital K Shah; Jerome A Langer; Faruk Sheikh; Harold Dickensheets; Raymond P Donnelly
Journal:  Nat Immunol       Date:  2002-12-16       Impact factor: 25.606

2.  Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

Authors:  Masao Honda; Akito Sakai; Tatsuya Yamashita; Yasunari Nakamoto; Eishiro Mizukoshi; Yoshio Sakai; Taro Yamashita; Mikiko Nakamura; Takayoshi Shirasaki; Katsuhisa Horimoto; Yasuhito Tanaka; Katsushi Tokunaga; Masashi Mizokami; Shuichi Kaneko
Journal:  Gastroenterology       Date:  2010-04-29       Impact factor: 22.682

3.  Treatment of acute hepatitis C with interferon alfa-2b.

Authors:  E Jaeckel; M Cornberg; H Wedemeyer; T Santantonio; J Mayer; M Zankel; G Pastore; M Dietrich; C Trautwein; M P Manns
Journal:  N Engl J Med       Date:  2001-11-15       Impact factor: 91.245

4.  Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals.

Authors:  Martin Vogel; Jacob Nattermann; Axel Baumgarten; Gerd Klausen; Bernhard Bieniek; Knud Schewe; Heiko Jessen; Christoph Boesecke; Michael Rausch; Thomas Lutz; Stefan Fenske; Dietmar Schranzo; Tim Kümmerle; Christoph Schuler; Albert Theisen; Christoph Mayr; Thomas Seidel; Jürgen K Rockstroh
Journal:  Antivir Ther       Date:  2006

5.  Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics.

Authors:  Tobias Marcello; Arash Grakoui; Giovanna Barba-Spaeth; Erica S Machlin; Sergei V Kotenko; Margaret R MacDonald; Charles M Rice
Journal:  Gastroenterology       Date:  2006-10-01       Impact factor: 22.682

6.  Interferon signaling and treatment outcome in chronic hepatitis C.

Authors:  Magdalena Sarasin-Filipowicz; Edward J Oakeley; Francois H T Duong; Verena Christen; Luigi Terracciano; Witold Filipowicz; Markus H Heim
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-08       Impact factor: 11.205

7.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

8.  Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yasuhito Tanaka; Nao Nishida; Masaya Sugiyama; Masayuki Kurosaki; Kentaro Matsuura; Naoya Sakamoto; Mina Nakagawa; Masaaki Korenaga; Keisuke Hino; Shuhei Hige; Yoshito Ito; Eiji Mita; Eiji Tanaka; Satoshi Mochida; Yoshikazu Murawaki; Masao Honda; Akito Sakai; Yoichi Hiasa; Shuhei Nishiguchi; Asako Koike; Isao Sakaida; Masatoshi Imamura; Kiyoaki Ito; Koji Yano; Naohiko Masaki; Fuminaka Sugauchi; Namiki Izumi; Katsushi Tokunaga; Masashi Mizokami
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

Review 9.  HIV and hepatitis C virus co-infection.

Authors:  Jürgen Kurt Rockstroh; Ulrich Spengler
Journal:  Lancet Infect Dis       Date:  2004-07       Impact factor: 25.071

10.  European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.

Authors:  J K Rockstroh; S Bhagani; Y Benhamou; R Bruno; S Mauss; L Peters; M Puoti; V Soriano; C Tural
Journal:  HIV Med       Date:  2008-02       Impact factor: 3.180
View more
  15 in total

1.  Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome.

Authors:  Christoph Boesecke; Patrick Ingiliz; Thomas Reiberger; Hans-Jürgen Stellbrink; Sanjay Bhagani; Emma Page; Stefan Mauss; Thomas Lutz; Esther Voigt; Marguerite Guiguet; Marc-Antoine Valantin; Axel Baumgarten; Mark Nelson; Martin Vogel; Jürgen K Rockstroh
Journal:  Infection       Date:  2016-02       Impact factor: 3.553

2.  Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men.

Authors:  Daniel S Fierer; Douglas T Dieterich; Michael P Mullen; Andrea D Branch; Alison J Uriel; Damaris C Carriero; Wouter O van Seggelen; Rosanne M Hijdra; David G Cassagnol
Journal:  Clin Infect Dis       Date:  2013-12-13       Impact factor: 9.079

Review 3.  Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions.

Authors:  Sreedhar Chinnaswamy
Journal:  J Interferon Cytokine Res       Date:  2014-02-20       Impact factor: 2.607

4.  Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis.

Authors:  Li-Sheng Wu; Hong Wang; Xiao-Ping Geng
Journal:  Exp Ther Med       Date:  2011-11-21       Impact factor: 2.447

5.  IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients.

Authors:  Mostafa K El Awady; Noha G Bader El Din; Ashraf Tabll; Yaser El Hosary; Ashraf O Abdel Aziz; Hesham El Khayat; Mohsen Salama; Tawfeek H Abdelhafez
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

6.  Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.

Authors:  María A Jiménez-Sousa; Amanda Fernández-Rodríguez; María Guzmán-Fulgencio; Mónica García-Álvarez; Salvador Resino
Journal:  BMC Med       Date:  2013-01-08       Impact factor: 8.775

Review 7.  The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals.

Authors:  Emma C Thomson; Jennifer A Smith; Paul Klenerman
Journal:  J Gen Virol       Date:  2011-07-20       Impact factor: 3.891

8.  IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients.

Authors:  Bruna C Bertol; Simone Moreira; Raquel F L Garcia; Leslie E Ferreira; Guilherme Debortoli; Mauro de Souza Leite Pinho; Marcia Amendola-Pires; Alessandra M de Almeida Maciel; Carlos E Brandço-Mello; Paulo H C de França
Journal:  Front Microbiol       Date:  2015-03-04       Impact factor: 5.640

9.  Lack of evidence to support the association of a single IL28B genotype SNP rs12979860 with the HTLV-1 clinical outcomes and proviral load.

Authors:  Sabri Saeed Sanabani; Youko Nukui; Juliana Pereira; Antonio Charlys da Costa; Ana Carolina Soares de Oliveira; Rodrigo Pessôa; Fabio Eudes Leal; Aluisio C Segurado; Esper Georges Kallas; Ester Cerdeira Sabino
Journal:  BMC Infect Dis       Date:  2012-12-23       Impact factor: 3.090

Review 10.  The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C.

Authors:  F Bellanti; G Vendemiale; E Altomare; G Serviddio
Journal:  Clin Dev Immunol       Date:  2012-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.